Evidence map›Paper›PMID 40207642›Full record

ArticleCancer communications (London, England)2025

Deciphering the transcriptomic landscape of early HR

Iris Garrido-Cano, Marta Tapia, Juan Carbonell, Carlos Peña, Sandra Torres-Ruiz, Anna Ágreda-Roca, Ana Lameirinhas, Cristina Tebar, Octavio Burgués, Cristina Hernando and 6 more

Abstract read
In one paragraph

Article in Cancer communications (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Iris Garrido-CanoBiomedical Research Institute INCLIVA, Valencia, Spain.ORCID https://orcid.org/0000-0002-1211-473X
Marta TapiaMedical Oncology Department, Hospital Clínico Universitario of Valencia, Valencia, Spain.
Juan CarbonellBiomedical Research Institute INCLIVA, Valencia, Spain.
Carlos PeñaBiomedical Research Institute INCLIVA, Valencia, Spain.
Sandra Torres-RuizBiomedical Research Institute INCLIVA, Valencia, Spain.
Anna Ágreda-RocaBiomedical Research Institute INCLIVA, Valencia, Spain.
Ana LameirinhasBiomedical Research Institute INCLIVA, Valencia, Spain.
Cristina TebarBiomedical Research Institute INCLIVA, Valencia, Spain.
Octavio BurguésBiomedical Research Institute INCLIVA, Valencia, Spain.
Cristina HernandoBiomedical Research Institute INCLIVA, Valencia, Spain.
Ana LluchBiomedical Research Institute INCLIVA, Valencia, Spain.
Fara Brasó-MaristanyTranslational Genomics and Targeted Therapies in Solid Tumors Group, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain.
Aleix PratTranslational Genomics and Targeted Therapies in Solid Tumors Group, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain.
Begoña BermejoBiomedical Research Institute INCLIVA, Valencia, Spain.
María Teresa MartínezBiomedical Research Institute INCLIVA, Valencia, Spain.
Juan Miguel CejalvoBiomedical Research Institute INCLIVA, Valencia, Spain.

Funding

Asociación Española Contra el CáncerBiomedical Research Networking Centre for Oncology CB16/12/00481European Union-Next generation EUFundación FEROJoan RodesMargarita Salas postdoctoral grantSEOM-Río Hortega 2023, and A.L. and A.A.SEOM: Sociedad Española de Oncología Médica
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40207642
PMCPMC12328086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.